1,809 reports of this reaction
1.4% of all EXENATIDE reports
#14 most reported adverse reaction
INJECTION SITE HAEMORRHAGE is the #14 most commonly reported adverse reaction for EXENATIDE, manufactured by AstraZeneca Pharmaceuticals LP. There are 1,809 FDA adverse event reports linking EXENATIDE to INJECTION SITE HAEMORRHAGE. This represents approximately 1.4% of all 130,422 adverse event reports for this drug.
Patients taking EXENATIDE who experience injection site haemorrhage should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE HAEMORRHAGE is a less commonly reported adverse event for EXENATIDE, but still significant enough to appear in the safety profile.
In addition to injection site haemorrhage, the following adverse reactions have been reported for EXENATIDE:
The following drugs have also been linked to injection site haemorrhage in FDA adverse event reports:
INJECTION SITE HAEMORRHAGE has been reported as an adverse event in 1,809 FDA reports for EXENATIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE HAEMORRHAGE accounts for approximately 1.4% of all adverse event reports for EXENATIDE, making it a notable side effect.
If you experience injection site haemorrhage while taking EXENATIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.